Abstracts tagged "rheumatoid arthritis (RA) and treatment options"

Abstract Number: 2512 • 2018 ACR/ARHP Annual Meeting
Treatment Continuation on the Etanercept Original in Comparison with a Biosimilar
Lisa Baganz¹, Yvette Meißner¹, Perter Herzer², Jürgen Braun³, Anett Gräßler⁴, Anja Strangfeld⁵ and Angela Zink⁶, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Scientific Advisory Board, Munich, Germany, ³Ruhr-University Bochum, Bochum, Germany, ⁴Rheumatologist, Pirna, Germany, ⁵Epidemiology, German Rheumatism Research Center, Berlin, Germany, ⁶Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany
Background/Purpose: The number of biosimilars approved for the treatment of rheumatoid arthritis (RA) is constantly increasing. Until now, there are just a few analyses investigating…
Abstract Number: 972 • 2017 ACR/ARHP Annual Meeting
JAK/STAT Mediated Inhibition of Mir-23a~24-2~27a Cluster Potentiates Activation of CD14+ Monocytes in Treatment-Resistant RA
Marina Frleta-Gilchrist, Donna McIntyre, Aziza Elmesmari, Lynn Stewart, Derek Baxter, Mariola Kurowska-Stolarska, Derek Gilchrist and Iain B. McInnes, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: While emerging and existing treatments of RA allow better options and clinical outcomes for patients, studies informing drug resistant states and further clinical therapeutic…
Abstract Number: 1430 • 2017 ACR/ARHP Annual Meeting
Switching from Synthetic to Biologic Dmards – Is There an Insufficient Use of Methotrexate?
Lisa Baganz¹, Adrian Richter¹, Yvette Meißner², Matthias Schneider³, Anke Liebhaber⁴, Ilka Schwarze⁵, Anja Strangfeld⁶ and Angela Zink⁷, ¹German Rheumatism Research Center, Berlin, Germany, ²Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ⁴Rheumatologist, Halle, Germany, Halle, Germany, ⁵Rheumatologist, Leipzig, Germany, Leipzig, Germany, ⁶Epidemiology, German Rheumatism Research Center, Berlin, Germany, ⁷German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: A recent US-study suggests considerable underuse of MTX and too early switches to biologic (b)DMARDs1 before using a high MTX dose or changing the…
Abstract Number: 626 • 2016 ACR/ARHP Annual Meeting
Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients
Branca Souza¹, Juliana Valim², Fernanda Chaer³, Fernanda Guimarães⁴ and Verônica Lima⁵, ¹Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ²Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil
Background/Purpose: Evaluate the reason of exchange of biologic therapy in patients with rheumatoid arthritis and describe the frequency of remission or low activity, according to…
Abstract Number: 2238 • 2016 ACR/ARHP Annual Meeting
RA Medication Preferences Among U.S. Patients in an Online Rheumatoid Arthritis Community
Baojin Zhu¹, Lawrence Chang¹, Leilei Qian¹, Cynthia J Larmore¹, Yoko Tanaka² and Andre B. Araujo¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapolis, KS
Background/Purpose: Medications used to manage RA vary in efficacy, safety, and convenience of use. A better understanding of patient preferences of these attributes is key…
Abstract Number: 2528 • 2016 ACR/ARHP Annual Meeting
Predictors of Long Term Survival of Low-Dose Etanercept: An Observational Study
Francesca Ometto¹, Bernd Raffeiner^2,3, Costantino Botsios², Davide Astorri⁴, Lara Friso², Livio Bernardi⁵, Leonardo Punzi⁶ and Andrea Doria², ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, PADOVA, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ³Rheumatology Unit, Internal Medicine, General Hospital of Bolzano, Bolzano, Italy, ⁴Rheumatology Unit, Department of Medicine - DIMED, University of Padova, padova, Italy, ⁵Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, ⁶Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Background/Purpose: The objective of the study was to investigate long-term survival of low-dose etanercept (ETN) (25 mg weekly) and possible predictors of survival. Methods: We…
Abstract Number: 597 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Different Anti-TNF Drugs As First Biological DMARD in RA: Results from the Nationwide Swedish Register 2010-2015
Thomas Frisell¹, Mats Dehlin², Daniela Di Giuseppe³, Nils Feltelius⁴, Alf Kastbom⁵, Carl Turesson⁶, Johan Askling⁷ and the ARTIS Study Group, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Clinical Epidemiology Unit, Dept. of Medicine, K2, Karolinska institutet, Stockholm, Sweden, ⁴Swedish Medical Products Agency, Uppsala, Sweden, ⁵Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, ⁶Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁷Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Although evidence from randomized trials suggest similar efficacy and safety on a group level for the different anti-TNF drugs available for the treatment of…
Abstract Number: 138 • 2015 ACR/ARHP Annual Meeting
Identification and Documentation of Secondary Osteoarthritis in Patients with Primary Inflammatory Arthritides Using a Patient MDHAQ/RAPID3 and a Physician Estimate of Joint Damage to Recognize Patient Complexity and Inform Management Decisions
Kathryn A. Gibson¹, Annie Huang², Katherine J. Bryant³ and Theodore Pincus², ¹Liverpool Hospital, Liverpool, Australia, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³University of New South Wales, Sydney, Australia
Background/Purpose: Patients with inflammatory arthritides may have secondary osteoarthritis (OA), which affects decisions concerning clinical management. For example, in one study, about 20% of patients…
Abstract Number: 144 • 2015 ACR/ARHP Annual Meeting
One-Year Costs Following Switching Versus Dose-Escalation Among Prevalent Tumor Necrosis Factor Inhibitors Used for Rheumatoid Arthritis
Tao Gu¹, Derek Tang², Gaurav Deshpande¹, Debra F Eisenberg¹ and David J. Harrison³, ¹HealthCore, Wilmington, DE, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Switching a biologic treatment or escalating biologic doses are common approaches used upon biologic treatment failure. The objective of this study was to estimate…
Abstract Number: 601 • 2015 ACR/ARHP Annual Meeting
Step-Down Strategy of Spacing TNF-Blockers Injections for Established Rheumatoid Arthritis in Remission: A within Randomized Control Trial Based Cost-Utility Analysis
Antoine Vanier¹, Florence Tubach², Toni Alfaiate³, Xavier Mariette⁴ and Bruno Fautrel⁵, ¹Biostatistics, Public Health and Medical Informatics, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6, Paris, France, ²Epidemiology and Clinical Research, AP-HP Bichat Hospital / University of Paris-Diderot / INSERM CIC-EC 1425, Paris, France, ³Epidemiology and Clinical Research, AP-HP Bichat Hospital / INSERM CIC-EC 1425, Paris, France, ⁴Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ⁵Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France
Background/Purpose: Once remission is achieved for patients with rheumatoid arthritis (RA), treatment down-titration should be attempted, for safety issues or economic reasons. One of the…
Abstract Number: 2541 • 2015 ACR/ARHP Annual Meeting
Improving Adherence with Treat to Target in Rheumatoid Arthritis through a Learning Collaborative: Rationale and Design of the Traction Trial
Daniel H. Solomon¹, Sara Lee², Agnes Zak², Jen Agosti³, Asaf Bitton⁴, Liana Fraenkel⁵, Leslie Harrold⁶, Elena Losina⁷, Bing Lu⁸, Theodore Pincus⁹, Josef S. Smolen¹⁰ and Jeffrey N. Katz¹¹, ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³JRA Consulting, Andover, MA, ⁴Medicine, Brigham and Women's Hospital, Boston, MA, ⁵Medicine, Yale University School of Medicine, New Haven, CT, ⁶Dept of Medicine, UMass Medical School, Worcester, MA, ⁷Orthopedics, Brigham and Women's Hospital, BU School of Public Health and Harvard Medical School, Boston, MA, ⁸Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ⁹Medicine-Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ¹⁰Medical University of Vienna, Vienna, Austria, ¹¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Treat to target (TTT) is a recommended paradigm in the management of rheumatoid arthritis (RA). However, various data sources suggest that TTT is…
Abstract Number: 2502 • 2014 ACR/ARHP Annual Meeting
Ten Year Follow-up Results of Four Dynamic Treat to Target Strategies in Patients with ACPA Negative Rheumatoid Arthritis
I.M. Markusse¹, G. Akdemir², L. Dirven², M. van den Broek², K.H. Han³, H.K Ronday⁴, P.J.S.M. Kerstens⁵, W.F. Lems^6,7, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, MCRZ hospital, Rotterdam, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁷Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: To determine the optimal treatment strategy in patients with anti-citrullinated protein antibodies (ACPA) negative (‒) rheumatoid arthritis (RA), as it has been suggested that…
Abstract Number: 2474 • 2014 ACR/ARHP Annual Meeting
Efficacy and Tolerability of Subcutaneous Methotrexate for Inflammatory Arthritis: A Retrospective Observational Cohort Study
Jessica Gunn, Aikaterina Panopolou and Alan Steuer, Rheumatology, Wexham Park Hospital, Slough, United Kingdom
Background/Purpose: Methotrexate (MTX) monotherapy or MTX in combination with other conventional and biologic disease-modifying antirheumatic drugs (DMARDs) is standard treatment for patients with inflammatory arthritis.…
Abstract Number: 2484 • 2014 ACR/ARHP Annual Meeting
Adding an Initial Six-Month Course of Infliximab to an Active Combination Treatment Is Cost Saving in Working-Aged Early Rheumatoid Arthritis Patients
Vappu Rantalaiho¹, Kari Puolakka², Janne Martikainen³, Hannu Kautiainen^4,5,6 and Marjatta Leirisalo-Repo^7,8, ¹Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland, ²Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ³Pharmacoeconomics and Outcomes Research Unit, School of Pharmacy, University of Eastern Finland, Kuopio, Finland, ⁴Department of General Practice, University of Helsinki, Helsinki, Finland, ⁵Unit of Primary Health Care, Turku University Hospital, Turku, Finland, ⁶Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, ⁷Department of Clinical Medicine, University of Helsinki, Helsinki, Finland, ⁸Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland
Background/Purpose To study the cost-effectiveness of adding initial infliximab to a remission-targeted combination treatment with disease modifying antirheumatic drugs (DMARDs) in early rheumatoid arthritis (RA).…
Abstract Number: 1497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Iguratimod for Rheumatoid Arthritis
Tsuneo Kondo¹, Akiko Shibata¹, Ryota Sakai¹, Kentaro Chino¹, Ayumi Okuyama¹, Hirofumi Takei¹ and Koichi Amano², ¹Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, ²Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].